One of the challenges in treating T-cell lymphomas
has been finding a way to eliminate the abnormal T-cells while sparing the healthy ones.
and positive in most subcutaneous panniculitis-like T-cell lymphomas
(Figure 4, B).
The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas
(PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas
(PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Compared with our patient group, higher rates of cutaneous NK/T-cell lymphomas
such as extranodal NK/T-cell lymphoma
and subcutaneous panniculitis-like T-cell lymphoma
(SPTCL) have been found in Korean and Japanese populations [22,23].
Conventional treatment of EATL consists of combination chemotherapy used for other aggressive T-cell lymphomas
such as CHOP.
We also looked at exposure to immunomodulators and risk of T-cell lymphoma
, the subtype we are most concerned about," Dr.
A T-Cell receptor [gamma] polymerase chain reaction assay using capillary electrophoresis for the diagnosis of cutaneous T-cell lymphomas
The therapeutic cytokine produced significant improvement in nearly 50% of cutaneous T-cell lymphoma
(CTCL) patients treated in recent phase I and phase II clinical trials, Dr.
These data provide strong rationale for our planned phase III clinical trial to evaluate ADCETRIS plus CHP compared to CHOP in front-line patients with mature T-cell lymphomas
," said Clay B.
However, rare cases of low-grade B-cell and T-cell lymphomas
can also present with scattered RS-like cells.
ClickPress, Thu Apr 09 2015] Global Markets Direct's, 'Peripheral T-Cell Lymphomas
(PTCL) - Pipeline Review, H1 2015', provides an overview of the Peripheral T-Cell Lymphomas
(PTCL)'s therapeutic pipeline.
Nasal T-cell lymphomas
are aggressive, locally destructive midfacial necrotizing lesions.
Peripheral T-cell lymphoma
represents a spectrum of T-cell lymphomas
and accounts for approximately 10 percent to 15 percent of all NHL cases in the United States.
Hepatosplenic T-cell lymphoma
(HSTL) is an aggressive T-cell lymphoma
that accounts for less than 1% of non-Hodgkin lymphoma and about 3% of all T-cell lymphomas